Polomar Health Services, INC 8-K filings

Polomar Health Services, Inc. announced the appointment of Douglas Beck as Chief Financial Officer and Treasurer, effective July 15, 2026.

Polomar Health Services, Inc. has dismissed GreenGrowth CPAs and appointed Haskell & White LLP as its new independent registered public accounting firm.

Polomar Health Services, Inc. announced a significant restructuring of its Board of Directors and the appointment of new executive officers, effective July 1, 2026.

Polomar Health Services, Inc. has mutually agreed with Altanine, Inc. to terminate their previously announced merger agreement, citing that the transaction is no longer in the best interests of shareholders.

Polomar Health Services has waived several closing conditions for its merger with Altanine, Inc. and amended its CEO's employment agreement.

Polomar Health Services received notice of intent to terminate a material distribution and marketing agreement with ForHumanity, Inc., citing alleged false representations.

Polomar Health Services, Inc. has amended its product fulfillment and distribution agreement with ForHumanity, Inc., extending exclusivity and establishing new revenue milestones and payment schedules.

Polomar Health Services, Inc. amended its merger agreement with Altanine Inc., revising the stock exchange ratio for common and preferred shares.

Polomar Health Services, Inc. has entered into an amended agreement granting ForHumanity, Inc. exclusive marketing rights for its inhalable sildenafil and eletriptan, contingent on revenue targets.

Polomar Health Services, Inc. has entered into a definitive merger agreement with Altanine Inc., which will result in Altanine becoming a wholly-owned subsidiary of Polomar and a significant shift in ownership and management.

Polomar Health Services, Inc. entered into a Promissory Note and Loan Agreement with affiliate CWR 1, LLC for up to $150,000, with an initial draw of $60,000, maturing by October 31, 2025.

Polomar Health Services, Inc. has formalized registration rights agreements with Reprise Management, Inc. and CWR 1, LLC, facilitating the future resale of common shares underlying Series A Convertible Preferred Stock.

Polomar Health Services, Inc. has issued $750,000 in Series A Convertible Preferred Stock to affiliated entities, Reprise Management, Inc. and CWR 1, LLC, to restructure existing debt and extend loan maturities.

Polomar Health Services announces the appointment of Charlie Lin as CFO and reports a delay in filing its annual report, now expected by April 30, 2025.

Polomar Health Services has signed an agreement granting ForHumanity Health exclusive marketing rights for its inhalable sildenafil and sumatriptan products, aiming to boost revenue through a strategic partnership.

Polomar Health Services will restate its financial statements for the period ended September 30, 2024, due to an SEC comment regarding the accounting treatment of its acquisition of Polomar Specialty Pharmacy.

Polomar Health Services has amended its patent license agreement with Pinata Holdings, securing a perpetual, non-exclusive worldwide license for key pharmaceutical ingredients.

Polomar Health Services files an amendment to its previous 8-K report to include details about the acquisition of Polomar Specialty Pharmacy and the assumption of its debt.

Polomar Health Services, Inc. finalized its acquisition of Polomar Specialty Pharmacy, LLC on September 30, 2024, making it a wholly-owned subsidiary.

Polomar Health Services, formerly Trustfeed Corp., has officially changed its name, increased its authorized preferred stock, and completed a 1-for-10 reverse stock split.

Trustfeed Corp. has finalized its acquisition of Polomar Specialty Pharmacy, marking a significant shift in its business operations towards telehealth and prescription compounding.

Trustfeed Corp. issued 10 million common shares to CRW 1, LLC after the full conversion of its Series A Convertible Preferred Stock.

Trustfeed Corp. has entered into a loan agreement with CWR 1, LLC for up to $250,000, with an initial draw of $157,622.56 used to repay prior undocumented loans.

Trustfeed Corp. has appointed Gabriel Del Virginia as a new director, effective July 18, 2024, to fill a board vacancy.

Trustfeed Corp. has approved a name change to Polomar Health Services, Inc., an increase in authorized preferred shares, a potential reverse stock split, and a new equity compensation plan via shareholder consent.

Trustfeed Corp. has secured a non-exclusive, worldwide license for intellectual property related to the delivery of several key pharmaceutical ingredients.

Trustfeed Corp. will merge with Polomar Specialty Pharmacy, with Polomar becoming a wholly-owned subsidiary and former Polomar members owning 75% of the combined company.

Trustfeed Corp. has appointed Terrence M. Tierney as a new director and interim executive, following the resignation of Brett Rosen from all positions.

Trustfeed Corp. reports the formal departure of director Rasmus Refer, effective February 12, 2024, following his resignation announced on December 29, 2023.